Myasthenia Gravis is an autoimmune disorder caused by autoantibodies against acetylcholine receptors in the neuromuscular junction. It is characterized by fluctuating weakness involving the eyes, throat, and extremities muscles. First-line treatment agents include peripheral AChE inhibitors (pyridostigmine and neostigmine) and immunosuppressors (prednisone). To avoid long-term corticosteroid therapy-related risks, non-steroidal immunotherapy (azathioprine or mycophenolate mofetil) is usually advised. Current treatment alternatives for patients with refractory disease include cyclosporine, cyclophosphamide, and surgical management with thymectomy. Despite the wide variety of available treatment options, a significant number of patients continue to be unable to respond to current medical interventions. In recent years, monoclonal antibodies (rituximab, ravulizumab, eculizumab) have acquired wide acceptance in the medical community, and their use has become essential for the optimal management of certain MG patients. This review aims to provide a comprehensive understanding of current and emerging therapies in the management of adults with generalized myasthenia gravis.